Richard S. Finn
0000-0003-2494-2126
Publication & Citation Trends
Publications
0 total
Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care
Cited by 0
Semantic Scholar
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study.
Cited by 0
Semantic Scholar
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study
Cited by 0
Semantic Scholar
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Cited by 0
Semantic Scholar
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies
Cited by 8
Semantic Scholar
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
Cited by 3
Semantic Scholar
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
Cited by 15
Semantic Scholar
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab OA
Cited by 17
Semantic Scholar
Research Topics
Hepatocellular Carcinoma Treatment and Prognosis
(328)
Advanced Breast Cancer Therapies
(128)
HER2/EGFR in Cancer Research
(100)
Cancer Immunotherapy and Biomarkers
(81)
Pancreatic and Hepatic Oncology Research
(76)
Affiliations
AstraZeneca (United Kingdom)
Northwestern University
University of Southern California
Santa Monica College
University of Modena and Reggio Emilia